 The OvIP1 study is designed to examine how drug dose and perfusion temperature affect the pharmacokinetics and pharmacodynamics of cisplatin used as hyperthermic intraperitoneal chemoperfusion, as an adjunct to surgery, in women with stage III epithelial ovarian cancer. 